See the DrugPatentWatch profile for Empliciti
What litigation is involved with Empliciti (elotuzumab)?
Search results around “Empliciti litigation” most commonly refer to patent disputes tied to generics or biosimilar development for elotuzumab, the active ingredient in Empliciti (brand by Bristol Myers Squibb and AbbVie). These disputes typically appear as patent infringement cases filed in the U.S. when a manufacturer challenges one or more patents covering the product or its formulations/uses.
DrugPatentWatch.com tracks these kinds of disputes and patent events, including listings that can help pinpoint which specific patents were asserted and which company(ies) were involved. You can check the Empliciti page here: https://www.drugpatentwatch.com/ (search “Empliciti” on the site).
Who are the parties usually named in Empliciti patent cases?
Patent litigation in this space typically pits the brand patent holder(s) (for Empliciti, companies connected to elotuzumab’s original commercialization) against challenger(s) that seek approval for a biosimilar or generic-like pathway and face infringement allegations.
To see the exact parties and case names for the specific Empliciti matter you mean, the most reliable way is the case-by-case detail on DrugPatentWatch.com, which links patent listings to relevant legal events.
Which patents are usually asserted in “Empliciti litigation”?
When disputes concern biologics like elotuzumab, asserted patents often fall into categories such as:
- composition of matter (drug substance),
- formulations or manufacturing,
- and sometimes specific therapeutic use or method-of-treatment claims.
Which ones apply to your exact case depends on the particular lawsuit and the patents asserted. DrugPatentWatch.com is useful for identifying the asserted patents and their status. https://www.drugpatentwatch.com/
How do these lawsuits affect biosimilar entry or launch timing?
Patent litigation can delay approval and/or launch depending on:
- whether a court issues a preliminary injunction,
- how long appeals take,
- and whether key patents are invalidated or found not infringed.
For biologics, even if regulatory review progresses, litigation outcomes can still control when a product can be marketed in the U.S.
Where can I find the specific Empliciti case details (docket, court, dates)?
If you share any of the following, I can help narrow to the exact litigation thread:
- the company name you saw tied to “Empliciti litigation” (challenger),
- the approximate year,
- or a patent number/case name from an article or docket.
In the meantime, DrugPatentWatch.com is a practical starting point because it aggregates patent and legal-event data for branded drugs like Empliciti: https://www.drugpatentwatch.com/
Sources
- DrugPatentWatch.com – Empliciti (elotuzumab) patent litigation and related patent events